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E-mail address: anne.simonsen@medisin.uio.no (AUbiquitinated protein aggregates are hallmarks of a range of human diseases, including neurode-
generative, liver and muscle disorders. These protein aggregates are typically positive for the
autophagy receptor p62. Whereas the ubiquitin-proteasome system (UPS) degrades shortlived and
misfolded ubiquitinated proteins that are small enough to enter the narrow pore of the barrel-
shaped proteasome, the lysosomal pathway of autophagy can degrade larger structures including
entire organelles or protein aggregates. This degradation requires autophagy receptors that link
the cargo with the molecular machinery of autophagy and is enhanced by certain posttranslational
modiﬁcations of the cargo. In this review we focus on how autophagy clears aggregate-prone pro-
teins and the relevance of this process to protein aggregate associated diseases.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Accumulation of ubiquitinated protein aggregates accompanies
several neurodegenerative disorders, as well as a number of other
protein aggregation diseases (proteinopathies) including those
affecting muscles, heart and liver. These aggregates consist of mis-
folded or aggregate-prone mutated versions of normal proteins,
exempliﬁed by the cytotoxic polyglutamine-expanded huntingtin
protein causing Huntington’s disease (HD). A well-characterized
pathway for the cell to degrade misfolded proteins is through the
ubiquitin-proteasome system (UPS), where misfolded proteins are
tagged with ubiquitin and targeted to the proteasome for degrada-chemical Societies. Published by E
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. Simonsen).tion. However, aggregate-prone proteins are poor substrates for
proteasomal degradation as proteins must pass through the narrow
barrel-shaped proteasome to be degraded [1,2]. Recent studies have
shown that also autophagy, a lysosomal degradation pathway for
intracellular material, can degrade misfolded proteins. There are
three different types of autophagy: chaperone-mediated autophagy
(CMA), microautophagy and macroautophagy. CMA involves direct
import of cytosolic proteins that contain a pentapeptide motif rec-
ognized by a chaperone leading to translocation into the lysosomes
[3]. Microautophagy involves direct uptake of cytoplasmic compo-
nents by invagination of the lysosomal membrane [4]. Macroauto-
phagy (hereafter referred to simply as autophagy) involves
expansion of a phagophore membrane which engulfs cytoplasmic
material as it closes to form a double-membrane vesicle, the auto-
phagosome (Fig. 1). After its formation, the autophagosome canma-
ture by fusion with endosomes to form amphisomes prior to fusion
with lysosomes or fuse directly with lysosomes to form the degra-
dative autolysosomes. There the originally cytoplasmic contents
are degraded and the resulting macromolecules are released to be
reused by the cell. The core molecular machinery of macroauto-
phagy was ﬁrst elucidated by elegant genetic studies in yeast
[4,5] and has later been progressively characterized in mammals.
The proteins found in the initial screens are named autophagy-re-
lated (Atg) proteins. Although the core autophagymachinery is well
conserved from yeast tomammals, differences exist and this review
will mainly focus on mammalian autophagy. Autophagy is induced
by stresses like starvation, to make the cell recycle its contents in
attendance of replenished nutrient supplies. In addition to thislsevier B.V. All rights reserved.
Fig. 1. Autophagy in mammalian cells. When autophagy is induced a phagophore membrane nucleates and expands to form an autophagosome, thereby engulﬁng part of the
cytoplasm, including cytosolic proteins, organelles and aggregated proteins. The autophagosome may fuse directly with lysosomes or mature by fusion with different
endocytic compartments (early endosomes, multivesicular bodies and late endosomes) to form amphisomes containing both autophagosomal and endosomal content. The
early endosome is a sorting compartment from where internalized cargo like nutrient receptors recycles back to the plasma membrane, whereas cargo destined for
degradation is sorted into the intraluminal vesicles of forming multivesicular bodies (MVBs). These MVBs then mature into late endosomes, which fuse with lysosomes for the
ﬁnal degradation of the internalized contents. This stepwise maturation of the endocytic compartments is associated with decreasing pH throughout the pathway. Fusion of
autophagosomes with each of these endocytic compartments also supports a stepwise fusion model of autophagosome maturation. Finally the autophagosomes or
amphisomes fuse with lysosomes where the originally cytoplasmic material becomes degraded and the resulting macromolecules recycled back to the cytosol to be reused by
the cell.
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that autophagy plays essential roles in development, immunity and
prevention of disease [6,7].
2. A brief introduction to the molecular core machinery of
autophagy
The mammalian autophagic machinery has already been exten-
sively reviewed [8,9] and only the main components are described
here. In brief, the nucleation and expansion of autophagic mem-
branes requires four groups of proteins: (1) the Atg1/unc-51-like
kinase (ULK) complex, (2) the Vps34/class III phosphatidylinositol
3-kinase (PI3K) complex I, which forms phospatidylinositol-3-
phosphate (PI3P), (3) the transmembrane protein mAtg9 and its
associated cycling machinery and (4) the two ubiquitin-like pro-
teins Atg12 and Atg8/MAP1 light chain 3 (LC3) and their conjuga-
tion systems.
2.1. Nucleation
The induction of autophagy is directly inhibited by the mamma-
lian Target of Rapamycin (mTOR) complex, which coordinates cellgrowth and autophagy [10]. mTOR activity is regulated by amino
acid and glucose levels and is inhibited by starvation. In the pres-
ence of sufﬁcient nutrients supplies, mTOR phosphorylates ULK1
and Atg13, thus inactivating the ULK1 complex [10]. But when
mTOR is inhibited by starvation or treatment with the drug rapa-
mycin, the ULK1 complex is activated and nucleation of autophagic
membranes can proceed. The nucleation additionally requires the
Vps34/class III PI3K complex I, which phosphorylates phosphati-
dylinositol to create PI3P [8]. Finally, the integral membrane pro-
tein mAtg9 must be recruited to the site of phagophore
nucleation [9]. The precise origin of the membranes composing
the phagophore is still under debate. But PI3P-positive structures,
called omegasomes, have been found to form from the endoplas-
mic reticulum (ER) and newly formed autophagosomes seem to es-
cape from these [11].
2.2. Expansion
Next, the phagophore expands and ﬁnally close to form the
autophagosome. Two ubiquitin-like conjugation systems are re-
quired for this expansion [12]. Analogous to ubiquitination, the
ubiquitin-like proteins Atg12 and LC3 are activated by an E1-like
H. Knævelsrud, A. Simonsen / FEBS Letters 584 (2010) 2635–2645 2637enzyme (Atg7) and conjugated by an E2-like enzyme (Atg10 and
Atg3, respectively) to Atg5 or phosphatidylethanolamine (PE),
respectively. The Atg12–Atg5 conjugate associates with mem-
brane-bound Atg16L to form a high molecular-weight complex.
Atg12–Atg5 works in an E3-like fashion for the conjugation of
LC3 to PE [13] and the Atg12–Atg5–Atg16L complex determines
the sites of LC3 lipidation [14]. Before LC3 can enter the conjuga-
tion pathway it has to be cleaved at its C-terminus to expose a gly-
cine residue. This cleavage is done by the cysteine protease Atg4
and the resulting cytosolic protein is called LC3-I. The PE-conju-
gated LC3 is called LC3-II. LC3-II was found to mediate membrane
tethering and hemifusion and likely contributes to phagophore
expansion, and it might also assist the ﬁnal fusion to close the
autophagosome [15]. The proteins required for nucleation and
expansion of autophagic membranes are retrieved from the form-
ing autophagosome, with the exception of LC3. LC3-II is inserted
into both leaﬂets of the forming autophagosome. Whereas LC3-II
on the outer leaﬂet is retrieved through delipidation by Atg4,
LC3-II on the inner leaﬂet remains bound to autophagic mem-
branes throughout the pathway and thus serves as an autophagic
marker protein.
2.3. Maturation
After its ﬁnal closure, the autophagosome matures by fusion
with endocytic compartments, creating amphisomes [16], but
autophagosomes may also fuse directly with lysosomes. Both the
coat protein complex I (COPI) and the endosomal sorting complex
required for transport (ESCRT) have been shown to be required for
maturation of autophagosomes [17–19]. COPI is found at early
endosomes which function as a sorting station for endocytic cargo,
whereas ESCRTs are required for formation of multivesicular
bodies (MVB) and sorting of endocytic cargo targeted for lysosomal
degradation into MVBs. The fusion of autophagosomes with both of
these endocytic compartments supports a stepwise fusion model
or vesicle maturation [20], where each fusion step delivers compo-
nents facilitating further fusion steps (Fig. 1). As described above,
the Vps34/class III PI3K complex I is involved in nucleation of auto-
phagic membranes, but Vps34 can also engage in a related com-
plex, Vps34/class III PI3K complex II, which regulates the
maturation of autophagosomes [8]. Moreover, the endosomal
PI3P 5-kinase PIKfyve, has been shown to be involved in this mat-
uration [21,22], indicating that also endocytic membrane lipids are
important for proper autophagosome maturation.
Autophagosomes can form all over the cell cytoplasm, but must
trafﬁc to the perinuclear area to fuse with lysosomes, a process
shown to depend on microtubules and dynein [23–25]. This traf-
ﬁcking is especially important in neurons, where the site of auto-
phagosome formation might be located far from the lysosomes.
Autophagosomes or amphisomes tether, dock and fuse with lyso-
somes. Among others, the class C Vps complex, as well as Rab7
and Rab11 are involved in the fusion of autophagic vesicles with
lysosomes [26–29]. Recently, the Rab7-, PI3P- and LC3-binding
protein FYCO1 was found to promotes microtubule plus end-direc-
ted transport of autophagosomes [30], thereby connecting trans-
port of autophagosomes to the fusion with lysosomes.
3. Aggrephagy – selective autophagy of protein aggregates
3.1. Protein aggregates
Commonly observed human neurodegenerative diseases can be
subdivided into groups based on the predominant type of aggre-
gate-prone protein, such as tauopathies, synucleinopathies, poly-
glutamine-containing inclusions or TAR DNA binding protein-43
(TDP-43) proteinopathies. Moreover, aggregates are often struc-tured (amyloid) or amorphous and are typically composed of insol-
uble proteins that can be hyperphosphorylated and crosslinked.
Aggregate-prone proteins are thought to form microaggregates
that can be combined and deposited into larger aggregates of var-
ious size and structure. In mammalian cells, aggregated proteins
can be trafﬁcked by microtubule-dependent retrograde transport
to a perinuclear site of aggregate deposition called the aggresome
(Fig. 2). It has been proposed that aggresomes could be a long-term
storage solution for misfolded proteins waiting to be degraded by
autophagy [31] and their formation could enhance the efﬁciency
and selectivity of autophagic degradation of aggregated proteins.
However, not all kinds of protein inclusions or aggresomes can
be degraded by autophagy [32].
Aggregate-prone proteins are associated with cytotoxicity. In
addition to no longer performing their wild-type function, the ob-
served toxicity is thought to be a gain of function of these mutant
proteins [33]. The exact nature of the cytotoxic species is still de-
bated. Longer polyglutamine tracts in the aggregate-prone protein
huntingtin correlate with earlier onset of the associated disease
and higher aggregate propensity of mutant proteins [34]. This
has been taken as proof that it is the aggregates that are the cyto-
toxic species. Others argue that soluble oligomers or small oligo-
mers are more toxic and that aggresome or inclusion body
formation protects the cells from these toxic species [35,36].
Whether entire protein aggregates are directly degraded by
autophagy, or if autophagy rather degrades soluble aggregate pre-
cursors is still debated. Autophagy has also been implicated in the
dissolution of larger neuronal inclusions into smaller aggregates
[37]. If soluble aggregate precursors are removed by autophagy,
then the aggregates could also disappear because the equilibrium
would be shifted away from aggregate formation towards aggre-
gate dissolution [33]. However, protein aggregates larger than
1 lm have also been observed inside autophagic membranes
[38], indicating that the autophagic machinery can sometimes de-
grade entire aggregates. In this case, it is not known whether the
aggregates are sequestered by preexisting autophagic membranes
or if the autophagic machinery is recruited to the aggregates to
mediate local assembly of autophagic membranes around the
aggregate.
3.2. Selective autophagy
During starvation, autophagy is induced to recycle cellular com-
ponents and support cell survival until nutrients are replenished.
Therefore starvation-induced autophagy is thought to be a non-
speciﬁc process, randomly sequestering cytoplasmic components
[39]. However, autophagy also proceeds at basal levels, performing
important quality control functions by removing damaged organ-
elles and other substrates targeted for lysosomal degradation. It
has recently become evident that this basal autophagy involves
selective recognition of the autophagic cargo. The autophagic deg-
radation of mitochondria has been termed mitophagy, whereas
autophagic degradation of intracellular pathogens is known as
xenophagy. For autophagy-mediated clearance of protein aggre-
gates, the term aggrephagy was coined by the group of Seglen
and co-workers [40]. Selective autophagy pathways are also pres-
ent in yeast. Among these, the cytoplasm to vacuole targeting
(Cvt) pathway is a biosynthetic pathway that delivers the hydro-
lase aminopeptidase I to the vacuole. Although not present in
mammals, the Cvt pathway can serve as a model for selective
autophagy also in higher organisms [41]. The key factors are cargo
receptors that connect the cargo to the core autophagy machinery.
Also in mammalian cells, the speciﬁc targeting of mitochondria,
pathogens or protein aggregates raises the question of how the
autophagic machinery recognizes these substrates. At least part
of the answer lays in the recent discovery of proteins functioning
Fig. 2. Degradation of protein aggregates by autophagy. Newly synthesized proteins normally fold into functional proteins. However, in the case of misfolding, chaperones can
sometimes help refold the protein into its native conformation, but misfolded proteins are often targeted for degradation. K48-linked ubiquitination targets the misfolded
protein for degradation by the proteasome. There the proteins are unfolded to pass through the narrow pore of the barrel-shaped proteasome and the ubiquitin moieties are
recycled. Misfolded aggregate-prone proteins can also be degraded by autophagy or deposited at the aggresome. These two options are associated with K63-linked
ubiquitination. For transport to the aggresome, the ubiquitinated proteins are recognized by HDAC6 and transported along the microtubules in a dynein-dependent manner.
The aggresome thus protects the cell from the toxicity of aggregate-prone proteins and possibly facilitates the autophagic degradation of these proteins. For degradation by
autophagy, the autophagy receptors p62 and NBR1 bind to ubiquitinated proteins and self-polymerize through their PB1 domains to form p62 bodies. p62 interacts with the
autophagic protein LC3 through its LIR and then, in collaboration with the large PI3P-binding protein Alfy, promotes the degradation of these protein aggregates. p62 and Alfy
are also found in PML bodies in the nucleus and shuttle between the nucleus and the cytoplasm. In the nucleus, p62 is proposed to recruit proteasomes to nuclear aggregates
to facilitate their degradation.
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substrates. These autophagy receptors contain an LC3-interacting
region (LIR), mediating interaction with Atg8/LC3 family members
(LC3/GABARAP/GATE-16) and a domain recognizing the speciﬁc
substrate. Such autophagy receptors have been identiﬁed for the
degradation of ubiquitinated bacteria (NDP52) [42] and mitochon-
dria (NIX) [43], as well as for ubiquitinated protein aggregates (p62
and NBR1, described below) [44–46].
In addition to these aggrephagy-speciﬁc autophagy receptors,
aggrephagy relies in general on the same molecular core machin-
ery as non-speciﬁc starvation-induced autophagy. Neuron-speciﬁc
Atg5 or Atg7 knock-out mice accumulate ubiquitinated cytoplas-
mic inclusion bodies [47,48] and studies in ﬂies have shown that
ubiquitinated and p62-positive aggregates accumulate in the ab-
sence of the Vps34/PI3K regulator Vps15 or Atg8/LC3 [49–51].
Likewise, siRNA-mediated clearance of Vps34/PI3K itself or its
complex partner Beclin 1, inhibited autophagic clearance of an
aggregate-prone model protein and the same effect was observed
by treating these cells with Vps34/PI3K inhibitors [52]. In sum-mary, the Atg5 and LC3 conjugation systems, as well as the
Vps34/PI3K complex are required for autophagic degradation of
protein aggregates. However, autophagic clearance of an aggre-
gate-prone model protein can proceed even in the presence of ac-
tive mTOR [52], indicating that aggrephagy is regulated differently
than starvation-induced autophagy. For instance has insulin sig-
nalling, known to activate mTOR, been shown to lead to clearance
of aggregate-prone proteins [52].
3.3. p62 and NBR1
p62 and neighbour of BRCA1 gene 1 (NBR1) have a very similar
domain structure, with NBR1 being the larger of the two [53]. Both
p62 and NBR1 are themselves substrates of autophagy and are con-
tinuously degraded [44–46]. This requires their LIR motif, which
interacts with LC3 and explains how p62 and NBR1 function as
cargo receptors for autophagy. Their recognition of ubiquitinated
protein aggregates is mediated through the C-terminal ubiquitin-
associated domain (UBA). Finally, they both contain an
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hetero-oligomerize or interact with atypical protein kinase C iso-
forms and other binding partners [53]. In addition to being a cargo
receptor for protein aggregates, p62 has been proposed to act as a
cargo receptor for other ubiquitinated substrates, like ubiquitinat-
ed midbody remnants after mitosis [54] and ubiquitinated intra-
cellular bacteria [55]. Besides its role in autophagy, p62 acts as
an important scaffold or adaptor protein in other signalling path-
ways, like NF-jB signalling [56] and Nrf2-induced expression of
anti-oxidative response genes [57].
p62 (and NBR1) is required for the formation of ubiquitinated
protein aggregates (Fig. 2), also called p62 bodies, sequestosomes
or aggresome-like inducible structure (ALIS) [45,58,59] mediated
by its self polymerization and ubiquitin binding. These structures
contain misfolded ubiquitinated proteins and can be experimen-
tally induced by addition of the translational inhibitor puromycin
[60]. Sequestration of misfolded proteins into such aggregates
might prevent the misfolded, often toxic proteins from harming
other cellular proteins until they become degraded by autophagy
or the proteasome [59]. As described above, inhibition of autoph-
agy in mouse brain or liver by knockout of the Atg5 or Atg7 genes,
causes ubiquitinated protein inclusions to accumulate [47,48,61].
Atg7//p62/ mice have much less ubiquitinated protein inclu-
sions than Atg7/mice, showing that p62 is involved in formation
of the observed aggregates [62]. This is probably because in the ab-
sence of autophagy, p62 accumulates and sequesters ubiquitinated
proteins through its UBA domain, including those that would nor-
mally be degraded by the UPS [63]. Interestingly, the combined re-
moval of p62 and Atg7 in hepatocytes and neurons attenuated liver
impairment caused by autophagy deﬁciency, but had little effect
on neurodegeneration. p62 knockout mice show normal autophagy
and do not accumulate protein inclusions compared to wild-type
controls [62]. These effects might seem to contradict the role of
p62 in aggregate clearance, but can be explained by its aggre-
gate-promoting role. The lack of a signiﬁcant phenotype in these
mice can also be explained by the redundant function of NBR1.
Corresponding to autophagy-deﬁcient mice, autophagy-deﬁcient
fruit ﬂies show accumulation of ubiquitinated protein aggregates
[50,51,64]. These aggregates are positive for the Drosophila ortho-
logue of p62, Ref(2)P, and the aggregates disappear in autophagy
and Ref(2)P double mutants [51].
p62 is also a common component of ubiquitinated protein
inclusions found in human diseases, including Lewy bodies (Par-
kinson’s disease (PD)), neuroﬁbrillary tangles (Alzheimer disease
(AD)), Huntingtin aggregates (HD) and Mallory bodies (alcoholic
and nonalcoholic steatohepatitis) [65,66]. Immunostaining of p62
on histological samples can be employed as a diagnostic marker
for human degenerative diseases associated with protein aggre-
gates [67] and it will be interesting to learn whether accumulation
of p62 in these diseases is associated with dysfunctional
autophagy.
3.4. Alfy
In addition to p62 and NBR1, the large protein Alfy (autophagy-
linked FYVE protein, also known as WDFY3) is involved in degrada-
tion of protein aggregates by autophagy (Fig. 2). Alfy becomes re-
cruited from the nucleus to cytoplasmic ubiquitinated protein
aggregates also containing autophagic membrane markers upon
cellular stress like starvation and proteasome inhibition [68]. Alfy
was recently shown to interact directly with p62 and, similar to
p62 and NBR1, be required to recruit ubiquitinated proteins into
aggregates that become degraded by autophagy [69]. Alfy is a large
scaffolding protein containing several domains which can facilitate
recruitment of the autophagic machinery to the protein aggre-
gates; a PH domain, a p62-interacting BEACH domain [69], aPI3P-binding FYVE domain [68] and WD40-repeats engaged in
interaction with Atg5 [38]. In line with these results, it was re-
cently found that Alfy is recruited to intracellular inclusions where
it scaffolds a complex containing p62 and the autophagic effectors
Atg5, Atg12, Atg16 and LC3. Whereas loss of Alfy was found to in-
hibit inclusion clearance, its overexpression caused elimination of
aggregates in an Atg5-dependent manner, and led to protection
in a neuronal and Drosophila model of polyglutamine toxicity
[38]. These results corroborate previous studies reporting that fruit
ﬂies mutant for the Alfy homologue, blue cheese (Bchs), show re-
duced life span due to accumulation of ubiquitinated protein
aggregates in the brain [70]. It is not known if Alfy can recognize
the ubiquitinated aggregates directly or if it is recruited through
its interaction with p62.
3.5. HDAC6
Autophagy and the UPS both target misfolded proteins for deg-
radation. Proteolytic cross-talk clearly exists between the two
pathways, shown by autophagy acting as a compensatory degrada-
tion system when the UPS is blocked [71,72]. Histone deacetylase 6
(HDAC6), a tubulin deacetylase that binds ubiquitin via its C-termi-
nal BUZ-domain, was shown to mediate this effect, probably by
bringing proteins that would otherwise accumulate to the auto-
phagic machinery. Overexpression of HDAC6 in a ﬂy model of neu-
rodegenerative disease (Spinobulbar muscular atrophy caused by
polyglutamine repeat expansion in the androgen receptor), accel-
erated the degradation of the mutant aggregate-prone protein by
autophagy and protected the ﬂies from neurotoxicity [71]. HDAC6
is required for the formation of aggresomes by transporting mis-
folded proteins to the microtubule-organizing centre (MTOC) along
microtubules through interaction with dynein [73,74] (Fig. 2).
HDAC6 is also thought to mediate the transport of components
of the autophagic machinery to the aggresome, thus bringing the
machinery close to its substrates [72]. Recently, HDAC6 was also
found to promote the creation of an actin network that enhances
the fusion of autophagosomes and lysosomes [75]. This effect
was speciﬁc to basal quality-control autophagy and dispensable
for starvation-induced autophagy.
4. Regulation of autophagic degradation of protein aggregates
The degradation of aggregate-prone proteins by autophagy can
be regulated both at the level of the autophagic machinery and at
the level of the aggregates, but not much is known about this reg-
ulation. As mentioned above, aggrephagy seems to proceed inde-
pendent of mTOR signalling and might be regulated by insulin
signalling [52]. Reactive oxygen species (ROS), known to accumu-
late by age, has been found to inactivate Atg4, thus inhibiting
LC3 delipidation and potentially promoting autophagy [76]. How-
ever, although a clear correlation was found between reduced
autophagy levels, formation of ubiquitinated protein aggregates
and sensitivity to oxidative stress in Drosophila [50], further studies
are required to elucidate how ROS, as well as the p62-mediated
Nrf2-induced anti-oxidant response [57], regulates aggrephagy
and disease progression.
Several proteins of the autophagic machinery localize to the nu-
cleus and undergo nucleocytoplasmic shuttling to exert their func-
tion in the cytoplasm. Very little is known about how this
nucleocytoplasmic shuttling affects autophagy and no thorough
study of which of the autophagy associated proteins rely on nucle-
ocytoplasmic shuttling have been performed. Concerning the
aggregates, various post-translational modiﬁcations, like ubiquiti-
nation, acetylation and phosphorylation, have been shown to spe-
ciﬁcally enhance the degradation of the aggregate-prone proteins
by autophagy.
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The nucleus and cytoplasm are separated by the nuclear enve-
lope. Small water-soluble molecules and proteins smaller than
40 kDa can freely diffuse between the compartments through
the nuclear pores, whereas larger proteins must actively be trans-
ported. Nuclear import is usually mediated by importin-a binding
to a nuclear localization signal (NLS) and nuclear export by expor-
tin-1/CRM1 binding to a nuclear export signal (NES) of the shut-
tling protein. The assembly and disassembly of these complexes
is mediated by the GTP/GDP-bound status of the small GTPase
Ran [77].
The autophagic proteins found to undergo nucleocytoplasmic
shuttling so far are Beclin 1, diabetes- and obesity-regulated gene
(DOR), p62 and Alfy. The former two are required for starvation-in-
duced autophagy, whereas the latter two are implicated in more
speciﬁc forms of autophagy as described above. The ﬁrst autopha-
gic protein shown to rely on nucleocytoplasmic shuttling was Be-
clin 1 [78]. Beclin 1 is part of the PI3K complex and has a tumor
suppressive function [79]. It contains a NES motif which is required
for Beclin 1 to promote starvation-induced autophagy and inhibit
tumorigenicity [78]. Recently also DOR, a reported nuclear cofactor
of thyroid hormone receptors, was implicated in autophagy [80].
Upon starvation, DOR exits the nucleus to interact with LC3 family
members in the cytoplasm and promote autophagy [80]. Mutation
of the DOR NES motif restricted DOR to the nucleus even under
stress conditions and blocked induction of autophagy by
rapamycin.
Alfy localizes to the nucleus and nuclear envelope in HeLa cells,
but is redistributed to protein bodies in the cytoplasm upon starva-
tion or proteasomal inhibition [68]. In contrast to the predominant
nuclear localization of Alfy, p62 is found to shuttle continuously
between the nucleus and the cytosol at a high rate [81]. p62 was
recently found to interact directly with Alfy and to be required to
recruit Alfy from the nucleus to the cytoplasmic ubiquitinated
protein bodies [69]. This recruitment of Alfy from the nucleus is
essential for autophagic degradation of larger complexes of ubiqui-
tinated proteins. p62 contain two NLS and one NES motifs, and the
shuttling of p62 is modulated by its phosphorylation and aggrega-
tion status. At steady state, the majority of the p62 pool is found in
the cytoplasm, but this is rapidly changed by inhibition of nuclear
export [81]. Interestingly, most nuclear autophagy proteins identi-
ﬁed to date were found to localize to promyelocytic leukemia
nuclear bodies (PML-NBs), especially when exportin-1/CRM1-
dependent nuclear export was inhibited. PML nuclear bodies has
been associated with a broad spectre of nuclear processes, as tran-
scription, DNA repair, stress, proteolysis and apoptosis [82]. The
nuclear proteasome-mediated protein degradation occurs at a sub-
set of PML-NBs [83]. Both p62 and Alfy localize to PML nuclear
bodies and are required for the recruitment of ubiquitinated pro-
teins to these nuclear bodies [69] (Fig. 2). p62 has been suggested
to facilitate proteasome recruitment to these sites and thereby
help the degradation of nuclear ataxin-1 aggregates [81] (Fig. 2).
However, it cannot be excluded that p62 and Alfy export ubiquiti-
nated substrates to the cytoplasm for degradation by the autopha-
gic machinery. It will also be interesting to learn whether the
nuclear autophagic proteins undergo some kind of regulation or
modiﬁcation at the PML-NBs.
4.2. Ubiquitination
Several post-translational modiﬁcations of aggregated proteins
have been found to enhance their degradation through autophagy.
First, protein aggregates targeted by autophagy are generally ubiq-
uitinated. Ubiquitin chains come in different ﬂavours depending on
through which lysine residue the ubiquitin moieties are linked.K48-linked ubiquitin chains are a classical signal for degradation
via the UPS. It is not clear if autophagic degradation is signalled
through a speciﬁc ubiquitin-link. However, p62 and NBR1 have
been shown to preferentially recognize K63-linked ubiquitin
chains [46,84,85] and inclusions labelled with K63-linked ubiqui-
tin chains have been associated with autophagic degradation
[86]. Furthermore, HDAC6 also preferentially binds K63-linked
ubiquitin chains in vivo [87]. p62 is also known to interact with
the E3 ubiquitin ligase TRAF6, which catalyzes K63 polyubiquitina-
tion [56] and it is thus likely that TRAF6 could contribute to the
ubiquitination of protein aggregates degraded by autophagy. Thus,
cargo modiﬁed with K63-linked ubiquitination might therefore be
preferentially targeted to the autophagic degradation pathway.
Actually, ubiquitination alone might be sufﬁcient for autophagic
targeting via p62. Indeed, peroxisomes or a cytosolic model protein
(red ﬂuorescent protein) tagged with ubiquitin became targeted
for autophagic degradation in a p62-dependent manner [88].
4.3. Acetylation
Acetylation of mutant aggregate-prone huntingtin enhances its
degradation by autophagy [89]. In contrast, mutant huntingtin that
is resistant to acetylation strongly accumulates in the expressing
cells. Huntingtin is actually a nuclear protein and must be exported
to the cytoplasm to be degraded by autophagy. The described acet-
ylation is performed by nuclearly localized CREB-binding protein
(CBP), but it is not clear if the acetylation enhances the nuclear ex-
port of the mutant huntingtin or its actual degradation by the auto-
phagic machinery in the cytoplasm. It will be interesting to learn if
also other proteins can be targeted for lysosomal degradation
through acetylation.
4.4. Phosphorylation
In addition to acetylation, it was recently reported that phos-
phorylation by the IKK complex also enhances degradation of mu-
tant aggregate-prone huntingtin [90]. Phosphorylation of
huntingtin was found to regulate other post-translational modiﬁ-
cations like ubiquitination, SUMOylation and acetylation. The in-
creased degradation of phosphorylated huntingtin proceeded
both through the proteasome and the lysosome. However, in this
study IKK-mediated phosphorylation was more efﬁcient for wild-
type than mutant huntingtin, suggesting that the phosphoryla-
tion-driven clearance of mutant huntingtin is reduced. Previously
it has been found that phosphorylation of mutant aggregate-prone
polyglutamine proteins (ataxin-1, ataxin-3 and huntingtin) also
regulate their ability to get cleaved, aggregate and cause neurode-
generation [91–96].5. Autophagic degradation of aggregate-prone proteins in
disease
Basal autophagy is especially important in post-mitotic cells
like neurons and hepatocytes, which cannot get rid of their waste
through cell division. As previously discussed, inhibition of autoph-
agy in mouse brain or liver by knockout of the Atg5 or Atg7 genes,
causes ubiquitinated protein inclusions to accumulate [47,48,61].
Importantly, brain-speciﬁc suppression of autophagy causes neu-
rodegeneration even in the absence of aggregate-prone disease-
associated mutant proteins, showing that basal quality-control
autophagy is important to prevent neurodegeneration [47,48]. Sev-
eral neurodegenerative phenotypes are associated with accumula-
tion of protein inclusions, including polyglutamine diseases, PD,
frontotemporal dementia (FTD) and AD. Autophagy has been
implicated in all of these diseases.
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There are nine different polyglutamine diseases, all character-
ized by abnormal expansion of a polyglutamine tract in a speciﬁc
protein. The most common and best studied of these, HD, is caused
by aggregate-prone mutant forms of the protein huntingtin having
a polyglutamine tract of more than 37 glutamines. The disorder in-
volves neuronal loss in the striatum and cortex leading to gradual
loss of voluntary movement coordination and eventually death of
the patient. Longer polyglutamine tracts in huntingtin correlate
with earlier onset of the disease and higher aggregate propensity
of the mutant proteins [34]. Mutant full-length huntingtin and
N-terminal fragments thereof aggregate and become substrates
for autophagy [97–99]. Moreover, expression of aggregate-prone
mutant huntingtin has been found to increase autophagy in HD
mouse models and patients [100–102]. This induction of autoph-
agy can be explained by decreased mTOR activity and eIF2a phos-
phorylation [103,104]. Importantly, autophagy is speciﬁcally
important for the degradation of aggregate-prone mutant hunting-
tin and not wild-type soluble huntingtin [97]. Another aggregate-
prone polyglutamine protein, ataxin-3, causing spinocerebellar
ataxia type 3 (Machado-Joseph disease), was also found to be de-
graded by autophagy [105].
Another type of ataxia (lack of muscle control or coordination)
is caused by the polyglutamine disease protein ataxin-1, which
forms aggregates in the nucleus. Polyglutamine expanded versions
of ataxin-1 are the etiological factors of spinocerebellar ataxia 1
(SCA1). If and how nuclear aggregates are degraded by autophagy
is currently debated in the ﬁeld. Proteasomes are present in the cell
nucleus, but lysosomes are not. Huntingtin is also found in the nu-
cleus, and aggregate-prone mutant versions of huntingtin must be
exported to the cytoplasm to be degraded by autophagy. As de-
scribed above, this might be regulated by acetylation and phos-
phorylation of huntingtin [89,90]. Autophagy has been shown to
eliminate cytoplasmic polyglutamine-containing aggregates more
efﬁciently than nuclear aggregates [106] and this differential efﬁ-
ciency of degradation could explain why nuclear aggregates are
more cytotoxic than cytoplasmic ones.
5.2. Parkinson’s disease
PD results from loss of dopamine-producing neurons causing
tremor, rigidity and impaired balance and coordination. Autophagy
has been found to be elevated in PD patient neurons [107]. PD is
characterized by the formation of neuronal aggregates called Lewy
bodies. The major protein constituent of these Lewy bodies is a-
synuclein, which can be degraded by the proteasome, macroauto-
phagy and CMA [108,109]. A30P and A53T mutations of a-synuc-
lein cause familial forms of PD [110]. These mutant proteins
were shown to bind the CMA receptor lysosomal associated mem-
brane protein type 2A (LAMP-2A) on the lysosomal membrane,
blocking their uptake by CMA and inhibiting their own degradation
as well as that of other substrates [109]. a-Synuclein undergoes
different types of posttranslational modiﬁcations, including dopa-
mine-modiﬁcation, which also inhibits the CMA-mediated degra-
dation of itself and other substrates [111].
5.3. FTD and amyotrophic lateral sclerosis (ALS)
Dysfunction of the autophagic machinery can also cause neuro-
degenerative disease. FTD is the most common form of presenile
dementia after AD, characterized by shrinking of the frontal and
temporal anterior lobes of the brain and either tau or ubiquitin
neuropathology [112]. ALS is a fatal disease characterized by death
of motor neurons, resulting in the ability of the brain to control
voluntary muscle movement being lost. Both diseases are associ-ated with ubiquitinated protein inclusions, formed by proteins like
tau, TDP-43 or SOD1, that also contain p62 [113]. Rare mutations in
the ESCRT subunit CHMP2B are associated with FTD and ALS in pa-
tients [114,115]. Individual deletion of several ESCRT components
resulted in accumulation of non-degradative autophagosomes in
nematodes, ﬂies or mammals [116]. Additionally, reduced ESCRT
function in a ﬂy model for HD aggravated polyglutamine-induced
neurotoxicity [21]. Furthermore, accumulation of ubiquitinated
protein aggregates was observed in cortical neurons of mice [19]
or in HeLa cells [17], expressing mutant CHMP2B. This mutation
corresponds to a rare patient mutation found in FTD patients,
underlining the importance of functional MVBs for proper auto-
phagic maturation and showing that a functional ESCRT machinery
is physiologically important for autophagy in mammals.
Point mutations of the p150 subunit of dynactin have also been
described in ALS patients [117]. Dynactin is essential for dynamin-
dependent transport on microtubules and as discussed above, dy-
nein function is important for autophagosome–lysosome fusion.
Dyneins are also mutated in some forms of motor neuron disease
and protein aggregation is present in some of these conditions,
possibly as an effect of compromised autophagy [33]. Indeed,
mutations in the dynein machinery impair autophagic clearance
of aggregate-prone proteins and enhance their toxicity in ﬂy and
mouse neurodegenerative models [118].
Finally, mutations in the hexameric chaperone p97/VCP cause a
dominantly inherited disease known as inclusion-body myopathy
with Paget’s disease of the bone and frontotemporal dementia
(IBMPFD), characterized by nuclear and cytoplasmic aggregates
in the brain and muscles of the patient [119]. The appearance of
aggregates has previously been thought to result from compro-
mised shuttling of ER associated degradation (ERAD) substrates
to the proteasome [120]. However, p97/VCP was recently impli-
cated in autophagy and compromised autophagy might contribute
to the symptoms observed in IBMPFD [121]. Interestingly, muta-
tions in p62 are also known to cause Paget’s disease of the bone,
although it is not known if this is linked to the role of p62 in
autophagy or rather its involvement in other signalling pathways
[53].
5.4. Alzheimer disease
Autophagosomes and autolysosomes have been found to accu-
mulate in dystrophic neurites of AD patients [122]. AD is the most
common form of dementia, starting with memory loss and confu-
sion, gradually leading to behaviour and personality changes and
eventually severe loss of mental function. AD is associated with
formation of extracellular plaques consisting of aggregated amy-
loid-b (Ab) peptide and intracellular neuroﬁbrillar tangles com-
posed of hyperphosphorylated tau. The Ab peptide is formed by
cleavage of the membrane protein amyloid precursor protein
(APP) by the enzymes b- and c-secretase. c-Secretase and Ab itself
has been found within autophagosomes, suggesting autophago-
somes to be a site of Ab production [123]. Indeed, Ab levels in-
crease upon induction of autophagy. The produced Ab would
normally be degraded in the lysosome [124], but the increased for-
mation of autophagosomes combined with impeded turnover of
these vesicles creates favourable conditions for Ab accumulation
and appearance of AD symptoms [123].
5.5. Mallory-Denk bodies (MDBs) in chronic liver diseases
Diseases that involve ubiquitinated protein aggregates are not
only neurodegenerative. There are also examples of ubiquitinated
protein aggregates found in muscle and liver disease. In the liver,
MDBs are found in patients with diverse chronic liver diseases,
including alcoholic and non-alcoholic steatohepatitis [125]. MDBs
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nents of the cytoskeleton composed of different types of proteins
and are involved in the maintenance of cell shape, locomotion
and intracellular trafﬁcking. Pathophysiologically, aggregation of
several different IF subunits is associated with human disease
[126]. IFs are also regularly found in aggresomes [31]. MDBs are
composed of aggregated abnormal keratins and p62 is found to
be required for their formation in cell culture [127]. By immuno-
histochemistry it was shown that MDBs are also positive for
NBR1 [46]. Autophagy was found to be increased in a mouse model
of MDBs and further induction of autophagy by rapamycin in-
creased the clearance of these aggregates [128].
In summary, the different types of disease-associated protein
aggregates mentioned are substrates for autophagy. Some aggre-
gates are also formed due to autophagic dysfunction. The degrada-
tion of these disease-associated aggregates depends on p62 and
the core autophagic machinery. Consequently, by learning more
about the mechanisms of autophagic degradation of one type of
aggregates, the knowledge can likely be applied to several types
of aggregates.6. Treating protein aggregate associated diseases by
manipulating autophagy?
The neurodegenerative phenotype of diseases involving aggre-
gate-prone proteins seems to depend on the continuous presence
of the mutant protein. Neurodegenerative symptoms in a mouse
HDmodel have been shown to be alleviated by direct RNA interfer-
ence targeting the mutant huntingtin [129]. Interestingly, halting
expression of the mutant aggregate-prone protein in symptomatic
mice was found to cause disappearance of the inclusions and a
complete reversal of the neurodegenerative symptoms in mouse
models of HD and SCA1 [130,131]. Therefore it is postulated that
removing the aggregate-prone proteins would cure patients of
neurodegenerative symptoms. The removal could happen either
by stopping the expression of the aggregate-prone protein or
enhancing its degradation. As we have seen, autophagy can de-
grade protein aggregates. Thus, induction of autophagy could be
envisaged as a treatment option for patients suffering from protein
aggregate associated diseases, provided that there is no down-
stream block in the autophagy pathway. If such a block at the lyso-
some level exists, increasing autophagy may actually aggravate the
condition.
Expression of autophagy genes has also been seen to decrease
with ageing, simultaneous with an increase in intracellular, ubiqui-
tinated protein aggregates [50,132]. Most protein aggregate associ-
ated diseases are also late-onset [133]. The decrease in autophagic
activity with age would probably aggravate the disease state by re-
duced clearance of the aggregate-prone proteins. Fruit ﬂy experi-
ments showed that genetic promotion of autophagy in the brain
of adult ﬂies reduced the amount of oxidized and ubiquitinated
protein species [50]. These effects were also accompanied by in-
creased ﬂy lifespan.
Gene therapy in humans is not an immediate option for treating
neurodegenerative diseases by inducing autophagy. However,
autophagy can also be induced by drugs. The mTOR inhibitor rap-
amycin is frequently experimentally used to induce autophagy and
is currently in clinical use, although not speciﬁcally to induce
autophagy [33]. Ravikumar and colleagues showed that mTOR
inhibition induced autophagy and reduced toxicity of mutant
aggregate-prone huntingtin in fruit ﬂy and mouse HD models
[103]. Actually, mTOR inhibition through rapamycin treatment
alleviates toxicity of different aggregate-prone proteins, including
those found in polyglutamine diseases, PD and some forms of
FTD [134]. The treatment with rapamycin reduces the levels ofboth soluble and aggregated proteins. An additional cytoprotective
effect of rapamycin is that it protects the cells against apoptotic in-
sults, probably through increased removal of mitochondria by
mitophagy [135]. However, mTOR controls many other pathways
in addition to autophagy and long-term use of rapamycin brings
certain side effects, like immunosuppression (this effect is used
to prevent rejection of the transplant in renal transplant patients).
Thus inducing autophagy without inhibiting mTOR would be desir-
able. mTOR-independent autophagy pathways and drugs have
been described [136,137]. For instance, lithium induces autophagy
by reducing intracellular inositol levels [138]. Additionally, in-
creased efﬁciency of autophagy induction can be expected by com-
bining mTOR inhibition through rapamycin analogues with mTOR-
independent small molecule enhancers [139]. However, keeping in
mind the problems associated with accumulation of autophago-
somes in AD, it is important not only to induce autophagy, but to
ensure proper ﬂux throughout the autophagic pathway.
In addition to general activation of the autophagy pathway, spe-
ciﬁc degradation of aggregate-prone proteins could be envisaged
by enhancing the posttranslational modiﬁcations that promote
their degradation. For instance, enhancing acetylation of mutant
huntingtin improves its degradation by autophagy and reverses
the toxic effects in primary striatal and cortical neurons [89]. HDAC
inhibitors might be used to enhance acetylation in general. We are,
however, currently not aware of any direct agent to enhance the
speciﬁc acetylation of mutant huntingtin, but discovery of drugs
that enhance this or other posttranslational modiﬁcations that pro-
mote clearance of aggregate-prone proteins could beneﬁt future
patients.
7. Concluding remarks
From the initial idea of a random non-selective process,
autophagy has emerged as a collection of many selective path-
ways targeting speciﬁc cargo for degradation. Moreover, autoph-
agy has been established as an alternative pathway to the UPS
for degradation of ubiquitinated proteins, specializing in the deg-
radation of aggregate-prone proteins. This degradation requires
the autophagy receptors p62 and NBR1 that are also found to
localize to various protein aggregates associated with human dis-
eases. In general, inducing autophagy seems to promote aggregate
clearance and alleviate the cytotoxic effects of aggregate-prone
proteins across many of these diseases, although imbalance in
the autophagic ﬂux can be harmful. To develop better tools to en-
hance degradation of aggregate-prone proteins by autophagy and
potentially employ these in therapy, we need greater insight into
the mechanisms governing how these proteins are targeted for
autophagic degradation.
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